Replimune Group, Inc. (7R8)
XSTU
Closed
Oct 2, 2026
Day's Range
11.3652 wk Range
1.28Overview - 7R8 - Replimune Group, Inc.
Key Statistics
Valuation
Enterprise Value
-97.43M
P/E (Trailing)
‪-3.40‬
PEG Ratio
‪0.14‬
Price / Book
‪10.53‬
EV / EBITDA
‪0.30‬
Profitability
Return on Assets
‪-94.44%‬
Return on Equity
‪-188.93%‬
Ownership
Shares Outstanding
83.97M
Price stats
50-Day Avg
‪11.18‬
200-Day Avg
‪7.55‬
Peers - 7R8 - Replimune Group, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- 7R8XSTUReplimune Group, Inc.+65.72%52-week change-3.40P/E (Trailing)—Profit Margin
- 0QFXSTUModerna Inc.+85.97%52-week change-23.23P/E (Trailing)‪54.83%‬Profit Margin
- 0MEXSTUTwist Bioscience Corporation+85.77%52-week change-123.50P/E (Trailing)‪50.72%‬Profit Margin
- 2LBXSTUIovance Biotherapeutics Inc.+85.40%52-week change-12.00P/E (Trailing)‪34.27%‬Profit Margin
- 3920XSTUSpyre Therapeutics, Inc.+83.21%52-week change-40.91P/E (Trailing)—Profit Margin
- 3O8XSTUOmeros Corp.+76.73%52-week change-329.00P/E (Trailing)—Profit Margin
- 87EXSTUDianthus Therapeutics Inc.+62.31%52-week change-18.57P/E (Trailing)—Profit Margin
Profile Summary - 7R8 - Replimune Group, Inc.
About
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
